Hepatitis C Infection Clinical Trial
Official title:
A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be the last on-study visit. After the Week 24 visit, all subjects with undetectable HCV RNA will be given the option to continue treatment with standard of care for an additional 24 weeks (out to Week 48) under the care of their Principal Investigator.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01771653 -
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
|
N/A | |
| Recruiting |
NCT03601546 -
Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam
|
||
| Completed |
NCT02362217 -
A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
|
Phase 1 | |
| Completed |
NCT00513461 -
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
|
Phase 2 | |
| Active, not recruiting |
NCT02143401 -
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02247401 -
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
|
Phase 3 | |
| Completed |
NCT02582632 -
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
|
Phase 3 | |
| Terminated |
NCT01532908 -
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
|
Phase 2 | |
| Recruiting |
NCT01754961 -
Effects of Vitamin D on Inflammation in Liver Disease
|
Phase 2 | |
| Terminated |
NCT01465516 -
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
|
N/A | |
| Completed |
NCT04042740 -
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT05601518 -
Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study.
|
||
| Terminated |
NCT02429583 -
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
|
Phase 4 | |
| Not yet recruiting |
NCT05506475 -
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
|
||
| Terminated |
NCT01841502 -
Interaction Between Paroxetine and Telaprevir
|
Phase 2 | |
| Withdrawn |
NCT02112630 -
Boceprevir in End Stage Renal Disease (ESRD)
|
N/A | |
| Completed |
NCT02076100 -
Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)
|
Phase 1 | |
| Completed |
NCT01803308 -
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
|
Phase 1 | |
| Terminated |
NCT01560468 -
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
|
Phase 1 | |
| Active, not recruiting |
NCT02772003 -
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
|
Phase 1 |